Page last updated: 2024-09-03

glycyl-glycyl-cysteine and copper gluconate

glycyl-glycyl-cysteine has been researched along with copper gluconate in 1 studies

Compound Research Comparison

Studies (glycyl-glycyl-cysteine)	Trials (glycyl-glycyl-cysteine)	Recent Studies (post-2010) (glycyl-glycyl-cysteine)	Studies (copper gluconate)	Trials (copper gluconate)	Recent Studies (post-2010) (copper gluconate)
7	0	2	3,657	233	653

Research

Studies (1)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	0 (0.00)	29.6817
2010's	1 (100.00)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Altai, M; Honarvar, H; Larsson, E; Löfblom, J; Lubberink, M; Orlova, A; Sandström, M; Ståhl, S; Strand, J; Strand, SE; Tolmachev, V; Varasteh, Z; Wållberg, H	1

Other Studies

1 other study(ies) available for glycyl-glycyl-cysteine and copper gluconate

Article	Year
188Re-ZHER2:V2, a promising affibody-based targeting agent against HER2-expressing tumors: preclinical assessment. Journal of nuclear medicine : official publication, Society of Nuclear Medicine, 2014, Volume: 55, Issue:11 Topics: Animals; Antibodies; Cell Line, Tumor; Chelating Agents; Drug Evaluation, Preclinical; Female; Gluconates; Humans; Mice; Mice, Nude; Oligopeptides; Ovarian Neoplasms; Peptides; Radiation Dosage; Radioisotopes; Radiometry; Radiopharmaceuticals; Receptor, ErbB-2; Rhenium; Xenograft Model Antitumor Assays	2014

Article

Year

188Re-ZHER2:V2, a promising affibody-based targeting agent against HER2-expressing tumors: preclinical assessment.

Journal of nuclear medicine : official publication, Society of Nuclear Medicine, 2014, Volume: 55, Issue:11

Topics: Animals; Antibodies; Cell Line, Tumor; Chelating Agents; Drug Evaluation, Preclinical; Female; Gluconates; Humans; Mice; Mice, Nude; Oligopeptides; Ovarian Neoplasms; Peptides; Radiation Dosage; Radioisotopes; Radiometry; Radiopharmaceuticals; Receptor, ErbB-2; Rhenium; Xenograft Model Antitumor Assays

2014